L’Oréal invests in biotech company Debut
©Debut
L’Oréal’s venture capital fund Bold has announced its latest investment in US biotech company Debut as it looks to rapidly scale the firm’s manufacturing platform. Through the funding, Debut is also looking to meet the growing demand for products made using biomanufacturing, building on the existing joint development programs of Debut and L’Oréal.
Debut’s IP portfolio has the ability to produce over 7,000 ingredients that can help to bring high-value, sustainable alternatives to the market faster, L’Oréal noted in a release, with the company particularly specializing in the end-to-end discovery, formulation, clinical trials, and the production of natural ingredients. Its platform allows such products to be created in larger quantities, implementing synthetic biology to reduce complexity and deliver ingredients in as few as six weeks.
The investment will enable Debut to rapidly scale its manufacturing platform and develop a wide variety of novel ingredients and beauty and personal care products using its proprietary cell-free and biotechnology model.
